Latest News
-

AMT-130 at Four Years: Hopeful Signs, Complex Controls
12 min read
uniQure reports that after 4 years, people given high-dose AMT-130 continue to show signs of slower HD progression, providing hope for their recent regulatory submission. But the new analyses are nuanced. We unpack the hopeful, but complex results.
-

EuroBuzz 2014 Video, day two
21 min read
Video of our second live session at the European Huntington's Disease Network Meeting.
-

Melatonin alterations in Huntington's disease help explain trouble with sleep
7 min read
Study shows HD patients have decreased levels of melatonin, which may explain why so many suffer from sleep problems
-

EuroBuzz 2014: day three
4 min read
Our third and final report on the 2014 European Huntington's Disease Network meeting in Barcelona
-

EuroBuzz 2014: day two
7 min read
HDBuzz reports on the second day of science at the European HD Network meeting in Barcelona
-

EuroBuzz 2014: day one
11 min read
Highlights from the opening day of the 2014 European Huntington's Disease network in Barcelona, Spain
-

Going toe-to-toe with tau: new insights into the chemical basis of Huntington’s disease
6 min read
Does tau protein – which causes problems in other neurodegenerative diseases – contribute to Huntington's disease?
-

New results bring BDNF therapies into focus
7 min read
Some unexpected findings suggest new ways to aim at an old target in HD
-

A starring role for astrocytes in Huntington's disease?
6 min read
Brain cells called astrocytes might play a bigger role than previously thought in Huntington's disease
-

HD mice provide a useful failure
5 min read
Can drug trials that fail be helpful? A HD mouse study provides solid evidence of an approach that doesn't help HD

